Planned intervention: On Wednesday June 26th 05:30 UTC Zenodo will be unavailable for 10-20 minutes to perform a storage cluster upgrade.
Published May 9, 2024 | Version v1
Publication Open

Recurrent/Disseminated Choroid Plexus Carcinoma: Overall Survival of > 23.6 Years in a One-Year and Nine-Month-Old Female Treated with Antineoplastons.

  • 1. Medical Division, Burzynski Clinic, Houston, Texas, USA
  • 2. Oncology Writings, Calera, Alabama, USA


Choroid plexus neoplasms (CPNs) are uncommon and have three types: papilloma, atypical papilloma, and carcinoma (CPC). There is no established treatment for recurrent/disseminated CPC. Objectives: CPN patients received treatment at the Burzynski Clinic (BC) according to the phase II protocol, BT-26, which aimed to evaluate the antitumor activity of ANP and to evaluate patient tolerance to ANP. Tumor response was assessed by sequential brain and spine MRIs utilizing gadolinium enhancement. Findings: After gross total resection of her CPC at another facility, this one-year and nine-month-old child, along with her parents, came to the BC for evaluation and treatment of the child’s recurrent/disseminated CPC. Baseline MRI of the brain (September 15, 2000) showed four enhancing lesions totaling 2.16 cm2 in size. Baseline MRI of the spine (August 28, 2000) showed enhancing but non-measurable dural lesions. Subsequent MRIs (December 14, 2000) showed enhancing brain tumors totaling 3.03 cm2 in size (a 40.3% increase from baseline) and enhancing dural lesions of the spine totaling 0.81 cm2 in size, indicating progressive disease. However, following ANP, this child has enjoyed > 23.6 years overall survival while experiencing good health. Conclusions: A very rare long-term survival with recurrent/disseminated CPC is presented and the usefulness of ANP is discussed.



Files (972.8 kB)

Name Size Download all
972.8 kB Preview Download